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ABSTRACT
Objectives: The aim of this study was to derive a scoring algorithm for a
validated disease-speciﬁc quality of life instrument called the Utility-Based
Questionnaire-Cancer (UBQ-C) that provided a utility index designed to
inform clinical decisions about cancer treatments.
Methods: The UBQ-C includes a scale for global health status (1 item);
and subscales for physical function (3 items), social/usual activities (4
items), self-care (1 item), and distresses because of physical and psycho-
logical symptoms (21 items). A scoring algorithm was derived to convert
the subscales into a subset index, and combine it with the global scale into
an overall health-related quality of life (HRQL) index, which was con-
verted to a utility index with a power transformation. The valuation
survey consisted of 204 advanced cancer patients who completed the
UBQ-C and assigned time trade-off (TTO) utilities about their own health
state. Preliminary validation involved comparing these derived utilities
with other measures of HRQL.
Results: Weights for the subset index were: physical function 0.28, social/
usual activities 0.06, self-care 0.01, and distresses 0.64. Weights for the
overall HRQL index were health status 0.65 and subset index 0.35. The
mean of the utility index scores was similar to the mean of the TTO
utilities (0.92 vs. 0.91, P = 0.6). The utility index was substantially corre-
lated with other measures of HRQL.
Conclusions: Data from a simple, self-rated, disease-speciﬁc question-
naire can be converted into a utility index suitable for comparing the net
effect of cancer treatments on quality of life, and to evaluate trade-
offs between quality and quantity of life in quality-adjusted survival
analyses.
Keywords: cancer, health-related-quality of life, health-state utility,
patient-derived preferences.
Introduction
Utility-based instruments are a common means of generating
utility scores for calculating quality-adjusted life-years (QALYs)
[1]. A utility-based instrument generally consists of a question-
naire which elicits responses about multiple dimensions of health
status and health-related quality of life (HRQL), and a scoring
algorithm that is used to convert the ratings on the questionnaire
into a single utility-based index [1,2]. The scoring algorithms for
utility-based instruments are valued in surveys, where subjects are
asked to assign utilities to the health states deﬁned by the ques-
tionnaire [1,2]. For example, the valuation survey for the EQ-5D
instrument involved lay people assigning utilities with the time
trade-off (TTO) method to a number of hypothetical health states
deﬁned in ﬁve generic dimensions (mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression) [3,4]. Utility-based
instruments may vary in the type of questions they contain
(generic or disease-speciﬁc), and the perspective from which the
scoring algorithm is valued (lay people or patient) [1,5,6].
Controversy exists about the suitability of generic versus
disease-speciﬁc utility-based instruments for generating utility
scores. Generic instruments like the EuroQol EQ-5D [3], Health
Utilities Index (HUI3) [7], or SF-6D [8] ask about core aspects of
HRQL that are of interest in a wide range of settings. The main
argument for using a generic utility-based instrument is that it
allows comparisons across a wide range of diseased and healthy
populations [9–11]. However, a generic instrument is likely to
provide an inadequate description of many diseases, so the utility
scores that it generates may be insensitive to differences between
individuals with that disease [9,12–14]. Disease-speciﬁc, utility-
based instruments were designed to address this lack of sensitiv-
ity by asking about speciﬁc aspects of HRQL relevant to that
disease or condition [6,12,15,16].
Controversy also exists about the suitability of utilities that
are valued from the perspective of lay people versus patients
[10,17,18]. The distinction is important because a patient typi-
cally assigns a higher utility to a health state than a lay person
[18–20]. Economic guidelines generally recommend the use of
generic utility-based instruments based on the perspective of lay
people [21–23]. The main argument for using the perspective of
lay people for informing funding and policy decisions is that the
primary objective in a publicly funded health system is to maxi-
mize health for society [1]. It is generally recommended that the
perspective of patients is used to inform clinical decision-making
[1,5,24,25]. The main argument for using the perspective of
patients for clinical decisions is that the primary objective is to
maximize health for the individual patient experiencing that
condition [26,27].
We posit that disease-speciﬁc instruments valued by patients
are preferable for informing clinical decisions, whereas generic
instruments valued by lay people may be preferable for decisions
about health policy.
The aim of this study was to derive a scoring algorithm for a
disease-speciﬁc, utility-based, HRQL instrument that is designed
to inform clinical decisions about cancer treatments. The algo-
rithm converts ratings from a cancer-speciﬁc HRQL questionnaire
into a utility-based index designed to reﬂect the perspective of
cancer patients. This article describes the development and preli-
minary validation of the algorithm. A companion article describes
the application of the algorithm to trial datasets, and illustrates
how it can be optimized in different treatment contexts [28].
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Methods
Source of Data
The valuation survey used to derive the scoring algorithm
involved ambulatory patients with advanced cancer and
impaired HRQL who were recruited from two tertiary-referral
oncology outpatient units [29]. Eligible patients had advanced
cancer, impaired HRQL, and were willing and able to complete
a self-administered HRQL questionnaire and participate in a
1-hour interview in English. All patients provided written
informed consent. The study was approved by the human
research ethics committees at all participating institutions.
Consenting patients were registered and scheduled for an
interview, usually on the day of their next appointment at the
oncology clinic. Utilities were elicited directly from subjects
about their current HRQL by one trained researcher using a
standardized, face-to-face, TTO interview with a hypothetical
survival time of 2 years. The TTO was expressed on the standard
continuum where 1 represents full health and 0 represents dead
[24]. Patients were mailed the questionnaire and asked to com-
plete it 3 to 7 days before the planned interview.
The Utility-Based Questionnaire-Cancer
The Utility-Based Questionnaire is a validated, disease-speciﬁc
HRQL questionnaire that was designed to be an outcome
measure for clinical trials in cancer and cardiovascular disease
[29–31]. The cancer version (the Utility-Based Questionnaire-
Cancer [UBQ-C]) includes 29 items about speciﬁc aspects of
HRQL, and a global scale called the health status thermometer,
which is a single item that asks respondents for a uniﬁed assess-
ment of their health status. The 29 items about speciﬁc aspects of
HRQL are grouped into subscales for physical function (3 items),
social/usual activities (4 items), self-care (1 item), and distresses
(21 items) because of physical and psychological symptoms asso-
ciated with cancer and its treatment.
The UBQ-C was designed for use in clinical trials of cancer
therapy, so it needed to be relevant to cancer patients, relatively
brief and easy to self-complete. The form and content of the
questionnaire build on the conceptual framework for health
status assessment developed by Gudex and Kind for an existing
generic preference-based instrument called the Health Measure-
ment Questionnaire (HMQ) [32]. The HMQ includes 36 items
covering ﬁve key dimensions of HRQL (general mobility, usual
activities, self-care activities, social and personal relationships,
and psychological distresses). A generic core set of items from the
HMQ was taken for the UBQ-C. Items less relevant for cancer
patients (e.g., hearing, vision, writing, speaking, and inconti-
nence) were discarded, and the response formats of some items
were modiﬁed. Cancer-speciﬁc items were selected for addition
by a review of existing literature on HRQL instruments used in
cancer patients [33,34]. Two measures of global health status
were also added. The health status thermometer is similar to the
graduated, vertical, visual analog scale that accompanies the
EuroQol EQ-5D questionnaire [35,36], but with the anchors of
“best imaginable health state” and “worst imaginable health
state” replaced by “full health” and “death,” to conform with
the requirements of a utility scale. The UBQ-C also includes the
general health item from the Short-Form-36 health survey (SF-
36) [37], which is a widely used and extensively validated
measure of generic health status [38]. The version of this item
used in the valuation survey described above omitted the
response category “very good.”
The psychometric properties of the UBQ-C in a cancer popu-
lation have been reported previously [29,31]. These include good
feasibility (high completion rate with little missing data), internal
consistency of subscales (Cronbach’s alphas >0.75 and conﬁrma-
tory factor analysis), test–retest reliability (intraclass correlation
coefﬁcients: median 0.85, lower quartile 0.81, upper quartile
0.90), convergent validity (substantial correlations with related
instruments: GLQ-8, GLQ-Uniscale [33], Priestman and Baum
LASA scales [34], and Life Satisfaction Index-A [39]), discrimi-
native ability (between groups with different disease severity),
and responsiveness to change within individuals.
Statistical Methods
The scoring algorithm was produced by modeling the valuation
survey data using the multistep approach developed by Lumley
et al. [40]. A “subset index” is calculated by combining the
questionnaire subscales into a subset index according to weights
based on their correlations with a global scale. Here we deﬁne a
global scale as a single item asking respondents directly for a
uniﬁed assessment of their HRQL [41]. An “overall HRQL
index” is then calculated by combining the subset index with this
global scale using weights based on their statistical precision.
Finally, a “utility index” is calculated by transforming the overall
HRQL index. A novel feature of Lumley’s approach that is not
incorporated in other approaches to deriving scoring algorithms
[1,2,42] is that it combines a single-item global scale with multi-
item subscales for speciﬁc aspects of HRQL. The purpose of
including the global scale in the index is to incorporate informa-
tion about any additional aspects of HRQL that are important
but not captured by the subset index [40].
The scoring algorithm for the UBQ-C was derived in four
steps (Fig. 1). First, subscale scores for physical function, social/
usual activities, self-care, and distresses were calculated from the
ratings on the relevant UBQ-C items. Second, a subset index was
calculated by weighted combination of the subscale scores.
Third, an overall HRQL index was calculated by weighted com-
bination of the subset index and the health status thermometer.
Fourth, the overall HRQL index was converted to a utility-based
index with a suitable transformation. The following paragraphs
describe each step in detail.
The subscale scores for physical function, social/usual activi-
ties, self-care, and distresses are the simple averages of the rel-
evant, nonmissing items, linearly transformed to a scale from
0 (worst) to 1 (best). Responses to the items about “Sex life”
and “Other problems” are not included when calculating the
scores for the subscales because they are commonly omitted by
respondents.
The subset index was calculated by weighted combination of
the subscales for physical function, social/usual activities, self-
care, and distresses. Weights for the subscales (W1–4 in Fig. 1)
were derived from, and proportional to, the coefﬁcients obtained
from multivariable ordinary least squares linear regression of the
health status thermometer on the subscales. The weights are
designed to reﬂect the relative contribution of each subscale to
overall HRQL. The scores for the subset index for each subject
were calculated by applying the weights to the subscale scores as
follows:
Subset index W PF W SA W SC
W DI
= ×[ ] + ×[ ] + ×[ ] +
×[ ]
1 2 3
4 (1)
W1–4 are the weights for the subscales: PF is physical function,
SA is social/usual activities, SC is self-care, DI is distresses. The
score for the subset index was recorded as missing if any of its
component scores were missing.
The overall HRQL index was calculated by weighted combi-
nation of the subset index with the health status thermometer.
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Greater weight was given to the component with least measure-
ment error. The weights were calculated using Lumley’s formula,
as follows:
W Var T 1 r T MSE R= ( ) × − ( )[ ] ( ) (2)
W is the weight allocated to the subset index, so 1 - W is the
weight allocated to the health status thermometer (Fig. 1). Var(T)
is the variance of the health status thermometer obtained from
the dataset. r(T) is the intraclass correlation coefﬁcient of the
health status thermometer, and was calculated with test–retest
data from a previous validation study [29]. MSE(R) is the mean
square for error from the linear regression of the health status
thermometer on the four subscales, and was obtained from the
dataset. The scores for the overall HRQL index for each subject
were calculated as follows:
Overall HRQL index W Subset index W HST= ×[ ] + −( ) ×[ ]1
(3)
HST is the health status thermometer. The scores for the overall
HRQL index were recorded as missing if the score for the subset
index or health status thermometer was missing.
A suitable transformation function was sought to convert the
overall HRQL index to the utility index. We considered a range
of functional forms used to transform measures of HRQL to
measures of utility in previous studies [43]. We selected the
function that best mapped the relationship between the overall
HRQL index and TTO utility in the development dataset. The
scores for the utility index for each subject were calculated by
applying the chosen transformation function to the scores for the
overall HRQL index.
Preliminary validation of the algorithm was performed by
comparing the scores on the utility index to those from other
measures of HRQL, health status, and utility. We assessed how
closely the utility index was related to the TTO utility using
Spearman’s rank-order correlation (rs) and paired t tests. Asso-
ciations between the utility index and two independent global
measures of HRQL, the general health item from the SF-36
(referred to above) and the Spitzer-Uniscale of global life quality
[44,45], were also assessed with Spearman’s rank-order correla-
tion. We tested the hypothesis that compared with related global
measures, the derived indices would give estimates of differences
in mean scores between subjects that were grouped by their
response to the general health item that were more precise (nar-
rower conﬁdence intervals) but unbiased (similar point estimate).
The overall HRQL index was compared with the health status
thermometer, and the utility index was compared with the TTO
utility. Differences in mean scores between groups were calcu-
lated using unpaired t tests. The relative precisions of the related
measures were compared using the relative efﬁciency statistic
[46,47]. The reciprocal of the relative efﬁciency statistic is the
factor by which the sample size can be reduced when a more
precise and therefore more efﬁcient scale is used. The relative
efﬁciency statistic was calculated as the squared ratio of the
t-score from the comparison of the groups using the derived
index divided by the t-score from the comparison of the groups
using the related global measure.
Results
The study proﬁle describing the subjects and data used to gener-
ate the scoring algorithm is shown in Figure 2. Of the 323
patients that were approached to take part in the study, 204 were
eligible. Compliance was excellent, with planned interviews and
questionnaires completed by 98% of participants. All items on
the UBQ-C, except “Sex life” and “Other problems,” were com-
pleted by over 90% of patients. Characteristics of eligible sub-
Overall
HRQL index
1-W
W1
W3
W1-4:
Weights of each subscale
determined by strength of association of
subscale with health status thermometer
Health status
thermometer
Physical
function
1 item
3 items
1 item
UBQ-C global scale
Subset
Index
W
1-W & W:
Weights of health status thermometer
and subset index are proportional
to their statistical precision
Social/usual
activities
Self-care
Distresses
4 items
21 items
W2
W4
Utility index
Transform
UBQ-C subscales
Figure 1 Deriving the overall health-related quality of life (HRQL) index and utility index from the Utility-Based Questionnaire-Cancer (UBQ-C) HRQL
questionnaire.
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jects are summarized in Table 1. All patients had advanced
cancer, mostly arising from the breast or bowel. The mean age
was 56 and most age groups were represented. The different
levels of general health status were also well represented. Most
modes of treatment were represented: chemotherapy, supportive
care, and observation.
UBQ-C ratings on the health status thermometer and sub-
scales are summarized in Table 2. Patients reported worst impair-
ment for physical function and least impairment for self-care.
The derived weights for the subscales (W1–4), health status
thermometer (W), and subset index (1-W) are shown in Table 3.
The health status thermometer accounted for about two-thirds of
the index for overall HRQL. Of the subscales, greatest weight
was given to distresses and least to self-care.
The overall HRQL index was calculated by applying these
weights to the subjects’ ratings on the UBQ-C using formulae (1)
and (3). The transformation that best reﬂected the relationship
between the overall HRQL index and TTO utility was a disutility
power transformation, viz:
Utility index overall HRQL index= − −( )1 1 2 03. (4)
This transformation was used to convert the overall HRQL index
into the utility index.
Scores for the overall HRQL index, utility index, and TTO
utility are compared in Table 4. The TTO utility was 1.0 for
about half the subjects, despite signiﬁcant impairments in
HRQL. Because of this skewed distribution, the mean value of
the TTO utility was lower than its median value. There were no
323 patients identified at clinic and 
given information package
204 questionnaires sent
119 patients ineligible
28 declined
30 too unwell
20 non-English speaking background
21 ineligible for logistic reasons
15 ineligible for other reasons
5 patients subsequently dropped
out or became too unwell
200 questionnaires received
199 patients completed interview
Figure 2 Study proﬁle.
Table 1 Patient characteristics (N = 204)
%
Cancer type
Breast 50
Bowel 29
Other 21
Age (years)
<40 12
40–49 21
50–59 25
60–69 28
70 14
Gender
Male 32
Female 68
Marital status
Partner 65
No partner (single, divorced, widowed) 35
Education
Primary school 4
Some high school 22
Completed high school 35
Higher education 39
Country of origin
Australia 80
Other 20
General health
Excellent 10
Good 48
Fair 35
Poor 7
Table 2 Ratings on the Utility-Based Questionnaire-Cancer health
status thermometer and subscales
Mean SD
Health status thermometer 0.74 0.16
Physical function 0.65 0.23
Social/usual activities 0.77 0.22
Self-care 0.95 0.14
Distresses 0.80 0.15
All ratings on scale from best (one) to worst (zero).
Table 3 Weights for the health status thermometer, subset index, and
subscales
Weight
W Health status thermometer 0.65
1-W Subset index 0.35
W1 Physical function 0.28
W2 Social/usual activities 0.06
W3 Self-care 0.01
W4 Distresses 0.64
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associations between the TTO utility and the patient character-
istics listed in Table 1 (data not shown).
The overall HRQL index gave substantially lower scores than
the TTO utility (means 0.74 vs. 0.92, difference 0.17, 95%
conﬁdence interval [CI] 0.14–0.19). Scores were similar for the
utility index and the TTO utility (means 0.92 vs. 0.91, difference
0.01, 95% CI -0.02–0.03).
Comparisons of the utility index with other measures of
HRQL, utility, and health status provide preliminary evidence of
its validity. The utility index was moderately correlated with the
TTO utility (rs 0.38), the general health status item from the
SF-36 (rs 0.63), and the Spitzer-Uniscale of global life quality (rs
0.68). The estimated differences in mean scores between subjects
grouped by general health in the development dataset were more
precisely estimated by the derived indices than by the health
status thermometer or the TTO utility (Fig. 3). The relative efﬁ-
ciency statistics in Figure 3 correspond with reductions in sample
size needed to detect a signiﬁcant difference by using the indices
of 33% for the overall HRQL index compared with the health
status thermometer, and of 75% for the utility index compared
with the TTO utility.
Conclusions
We have derived a scoring algorithm for a disease-speciﬁc utility-
based instrument that is designed to inform clinical decisions
about cancer treatments. The algorithm converts ratings from a
cancer-speciﬁc HRQL questionnaire called the UBQ-C into a
utility-based index. Firstly, the algorithm calculates a subset
index from a weighted combination of the UBQ-C subscales for
physical function, social/usual activities, self-care, and distresses.
Secondly, an overall HRQL index is calculated from a weighted
combination of the health status thermometer and the subset
index. Thirdly, the algorithm calculates a utility index by apply-
ing a power transformation to the overall HRQL index. The
scoring algorithm was developed using TTO utilities and UBQ-C
ratings elicited from patients with advanced cancer who rated
their current health status and HRQL. The utilities can be used to
generate QALYs to compare cancer treatments.
Utilities and QALYs are a useful way to compare cancer
treatments because they can be evaluated on a common scale that
incorporates disparate treatment effects like gains in survival
duration, improvements in HRQL because of relief of cancer
symptoms, and deteriorations in HRQL as a result of treatment-
related side effects [1,48]. Analyses of cancer trials in terms of
utilities and QALYs are increasingly used to inform economic
decisions about cancer treatments [49–56], but can also be used
to inform clinical decisions [57–62]. Despite the advantages of
utilities and QALYs, there is no standardized approach for elic-
iting utilities [1,24,63,64]. One way to obtain utilities is to elicit
them directly from respondents using a standard gamble or TTO
interview, but this task is complex, resource intensive, and can be
distressing if cancer patients are required to assign utilities for
their own health state [24]. A more practical approach is to
derive utility scores from a utility-based instrument. We posit
that deriving utility scores from a utility-based instrument that is
disease-speciﬁc and based on the perspective of patients is the
best approach for informing clinical decisions.
The UBQ-C is a disease-speciﬁc instrument that is designed for
the evaluation of cancer treatments. It asks about important
consequences of cancer and its treatment not covered by generic
instruments such as the EQ-5D [3], HUI3 [7], or SF-6D [8]
including fatigue, nausea, shortness of breath, and hair loss. The
main advantage of a disease-speciﬁc instrument such as the
UBQ-C over a generic instrument for generating utility scores is
that it should be more sensitive to detect differences in HRQL
between individuals with cancer. This requires empirical testing,
Table 4 Comparison of scores for overall health-related quality of life
(HRQL) index, utility index, and time trade-off utility
Statistic
Time trade-
off utility
Overall HRQL
index
Utility
index
Mean 0.91 0.74 0.92
Standard deviation 0.17 0.14 0.08
95% conﬁdence intervals (0.89, 0.94) (0.72, 0.76) (0.90, 0.93)
Median 1.00 0.77 0.95
Interquartile range (0.88, 1.00) (0.63, 0.86) (0.87, 0.98)
% with score of 1.0 50 0.5 0.5
Mean difference compared
to time trade-off utility
Not applicable 0.17 0.01
P value <0.0001 0.6
All ratings on scale from worst (0) to best (1).
Utility index
(t=8.5)
UTILITY 
MEASURES
Health status 
thermometer
(t=7.7)
Overall HRQL index
(t=9.4)
MEASURES OF 
GLOBAL HEALTH 
STATUS AND 
OVERALL HRQL
TTO utility
(t=4.3)
0.250.200.150.100.050.00-0.05-0.10
Difference in HRQL
Relative
efficiency
of overall
HRQL
index
= 1.5 
Relative
efficiency
of utility
index
= 3.9
Figure 3 Comparison of precision of: 1) overall health-related quality of life (HRQL) index and health status thermometer; and 2) utility index and time trade-off
(TTO) utility, in distinguishing subjects grouped by their general health status (excellent or good vs. fair or poor).All ratings on scale from 0 to 1. Relative efﬁciency,
reciprocal of factor by which sample size can be reduced when more efﬁcient index is used (see text); t, t-score for difference between groups.
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as has been performed for other disease-speciﬁc instruments that
generate utility scores for cancer [12,15,65] and a range of other
diseases including bladder disorders [6,16], hearing impairment
[66], and asthma [13]. Another advantage of using a disease-
speciﬁc utility-based instrument is that it provides data on speciﬁc
aspects of HRQL, overall HRQL and utility with a single ques-
tionnaire, and increases the availability of utility data for com-
parisons of treatment from randomized clinical trials [15]. This
approach enables utilities to be derived from previous studies
where the UBQ-C was used, and reduces questionnaire burden for
future trial participants by having a single questionnaire and
approach that provides these three kinds of information.
The major limitation of using disease-speciﬁc, utility-based
instruments is that the utility scores they provide may not be
comparable to those derived from other instruments, particularly
generic instruments, because the dimensions of health status and
HRQL that they cover are different [9–11]. Whether this is a
problem depends on the decision for which the utilities are being
applied. We argue that disease-speciﬁc instruments are best suited
to treatment comparisons within a particular disease used to
inform clinical decisions. In this context, comparisons across
other diseases and healthy populations are less important, but
coverage of aspects relevant to the patients under study is crucial.
Others have argued that disease-speciﬁc instruments may also be
suitable for treatment comparisons across all diseases to inform
health funding and policy decisions if the scoring algorithm is
derived using a valuation technique and population sample that
is similar to a generic instrument, and the utility scores are shown
to be comparable [6].
The algorithm described in this study was based on the per-
spective of cancer patients who were currently experiencing those
health states. The perspective differs in two important ways from
scoring algorithms used for most of the generic and cancer-
speciﬁc utility-based instruments reported previously. First, it is
the perspective of patients rather than lay people. Second, it
reﬂects views about a health state that is real and current rather
than hypothetical and in the future [67]. The perspective from
which a utility is elicited may have signiﬁcant implications for
clinical and economic decisions that incorporate utilities and
QALYs, because patients typically assign higher utilities to a
given health state than lay people [18–20]. This may reﬂect partly
the lay person’s difﬁculty appreciating what a hypothetical health
state is really like, and partly the patient’s adaptation to their
own health state [18,24,25,60,68]. The choice of perspective
should reﬂect the viewpoint from which the results will be inter-
preted [24,25]. As discussed in the introduction, it is generally
agreed that the perspective of patients is more appropriate for
informing clinical decisions about speciﬁc treatments, while the
perspective of lay people is more appropriate for informing deci-
sions about health policy and funding. Some also argue that the
perspective of patients should be used to inform funding and
policy decisions, because patients better understand what it is
like to live with a particular disease [17,19], but this argument is
controversial because it runs counter to prevailing health eco-
nomic guidelines [21,23,69].
This study also provides preliminary evidence supporting the
validity of the utility index. It was substantially correlated with
independent measures of general health, overall life quality, and
TTO utilities. Mean scores for groups from the utility index and
TTO utility were almost identical. This supports the validity of
using the utility index to generate mean utilities for comparing
patient groups. However, as expected, we found that the utility
index did not accurately predict utilities for individual patients.
The mean absolute difference between the utility index and TTO
utility for each subject was relatively large at 0.10. This ﬁnding
argues against using the utility index to predict utilities for indi-
viduals. This is exactly as expected [15], because utilities are
inﬂuenced by factors apart from HRQL such as individuals’
attitudes to risk and uncertainty [24,64].
The derived indices for HRQL and utility gave more precise
estimates of differences between groups than the health status
thermometer or TTO utility. We expected more precise estimates
because any score aggregated from multiple items will produce a
more precise estimate of differences between groups than a
single-item scale [40,70]. This ﬁnding does not strengthen or
weaken the validity of the indices but is an expected measure-
ment property which enhances the sensitivity and responsiveness
of the indices.
Ongoing work is needed to support the validity of the utility
index. A companion article describes the application of the
scoring algorithm to independent trial datasets in breast cancer,
and provides further evidence to support its validity by compari-
son with clinical data [28]. We have also reported on a compari-
son of the value and sensitivity of utility scores generated by
the index to those generated by the EQ-5D in colorectal cancer
[71]. Independent testing in other datasets will further establish
validity.
The study population and valuation survey used to develop
the scoring algorithm has several strengths. The patient charac-
teristics were diverse including men and women with a broad
range of ages, levels of performance status, and levels of health
status. Compliance was excellent with both UBQ-C completion
and utility interviews. We used the TTO method to elicit utilities
for health states. The TTO is practical, reliable, and has empiri-
cal validity [24,72,73]. A limitation of our valuation survey was
that its sample size was too small to allow division of the group
into a “training” set, where the algorithm was developed, and a
“validation” dataset where its validity and accuracy was inde-
pendently tested. The dataset was conﬁned to patients with
advanced cancer, mostly with breast or colorectal primaries, and
attending ambulatory clinics. This may raise questions about the
generalizability of the algorithm and approach to patients with
cancers that are of earlier stage, in remission, or from other
primary sites.
The novelty of our statistical approach is in its combination
of a single-item global scale with multiitem subscales for speciﬁc
aspects of HRQL and its methods for deriving optimal weights.
Most other utility-based indices do not incorporate a single-item
global scale [1,2,42]. Incorporation of the single-item global
scale has two potential advantages. First, it provides a uniﬁed
reﬂection of how the patient rates their health status that enables
incorporation of aspects of HRQL that are important but are not
directly captured by multi-item subscales [40]. Second, it allows
the scoring algorithm to be optimized in different treatment
contexts by adjusting the weights assigned to the multi-item
subscales [40]. The purpose of optimizing the algorithm is to
reﬂect the differences in importance that patients with different
types and stages of cancer, and treatments assign to various
dimensions of HRQL [40,74]. The implications of optimizing the
algorithm for different treatment contexts are addressed by appli-
cation and discussion in a companion article [28].
This work enables HRQL data obtained with a simple cancer-
speciﬁc questionnaire to be converted into a utility index that
reﬂects the perspective of cancer patients. The approach is best
suited to generating estimates of mean utilities for groups, and
our work so far supports this application. It can be applied in
clinical trials to compare the effect of cancer treatments on
HRQL using utility measures, and to generate QALYs for
informing clinical decisions and as an alternate viewpoint for
economic analyses. The approach provides a general method
Deriving a Patient-Based Cancer Utility Index 805
for converting HRQL ratings to valid utility-based measures that
could be applied in other trial settings for analysis of HRQL data
collected with different questionnaires.
Source of ﬁnancial support: Peter Grimison was supported by National
Health and Medical Research Council, Australia; Cancer Institute NSW,
Australia; and GlaxoSmithKline Australia. The funding agencies had no
role in the study design, the collection or analysis of the data, the inter-
pretation of the results, the preparation of the article, or the decision to
submit the article for publication.
Supporting information for this article can be found at: http://
www.ispor.org/publications/value/ViHsupplementary.asp
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